Search Weight Loss Topics:

Home » Uncategorized » Weight-Loss Drugs Fuel Rise in US Prescription Spending – Drug Topics

In 2023, prescription drug spending grew 13.6% compared with 2022 and semaglutide was the highest selling drug due to a recent increase of weight-loss classifications.

Expenditures for semaglutide doubled last year, making it the new top-selling drug in the US, replacing adalimumab, which treats autoimmune diseases like rheumatoid arthritis and Crohn's disease, wrote the American Society of Health-System Pharmacists in a press release.1 Adding to the weight-loss category, spending on the diabetes drug tirzepatide grew an astounding 373% even though its approval for weight loss came late in 2023.

Drugs like semaglutide and tirzepatide were originally classified as diabetes medications but have since been approved for weight-loss indications. According to researchers, the evolution of weight-loss medications is following a continuous trend of increased spending beyond 2023.

In 2024, they predict US prescription drug spending to increase another 10% to 12%. And while weight-loss drugs led the charge by the end of 2023, demand for endocrine and cancer drugs continues to fuel spending.2

READ MORE: Focus On Obesity Management Before Addressing Comorbidities

In 2023, Novo Nordisk saw combined sales of $21.1 billion from its drugs Wegovy, Ozempic, and Rybelsus. | image credit: K KStock / stock.adobe.com

Whether patients are using these drugs for weight-loss or diabetes management, in 2023, Novo Nordisk saw combined sales of $21.1 billion from its drugs Wegovy, Ozempic, and Rybelsus. This accounts for an 89% revenue increase for the Danish drug manufacturer from these 3 drugs alone, according to a Pew Research study.3

Furthermore, 71% of worldwide semaglutide sales came from the US, a country where almost 75% of adults over 20 are considered obese (42%) or overweight (31%).3

For now, the public has modest expectations for the impact drugs like Ozempic and Wegovy will have on obesity in the United States. Only 16% of those familiar with these drugs think they will do a great deal or quite a bit to reduce obesity, while 35% think they will do some and 33% expect they will do not much or nothing at all to reduce obesity in the US, wrote Tyson and Kikuchi regarding another Pew Research study.4

Between the mixed-use of drugs like semaglutide and tirzepatide for either weight-loss or diabetes, and the countrys modest sentiment supporting their use for weight-loss, what exactly Americans are using these drugs to treat is a bit uncertain.

Just 12% of those familiar with these drugs say they are good options for people who want to lose weight butdonothave a weight-related health condition. A far larger share (62%) say these drugs are not good options for people without a weight-related health condition, while 26% arent sure, continued Tyson and Kikuchi.4

These statistics show that the recent rise of semaglutide sales could be further enforced by increased marketing and public attention. Beverly Tchang, MD, endocrinologist, and assistant professor of clinical medicine at Weill Cornell Medicine and New York Presbyterian Hospital, recently expressed her concerns about weight-loss drugs in an Everyday Health article addressing a semaglutide shortage.

I worry more that people who do not have obesity or diabetes are buying semaglutide at its out-of-pocket cost to get skinnier, likely stirred on by TikTok videos or Variety articles. Patients with diabetes and patients with obesity both deserve treatment, and the shortage of semaglutide in general affects both populations, she said.5

But regardless of their preferred uses, the rise in semaglutide and tirzepatide sales have manufacturers ready to roll out a larger inventory of their weight-loss drugs and researchers are certain of their continued increase.2

Several new drugs that will influence spending are expected to be approved in 2024, wrote the authors.2 Because of their uses among diabetics, overweight individuals, and healthy individuals trying to lose weight, it is not nave to predict that weight-loss medications will occupy future lists of newly accepted medications.

READ MORE: Wegovy Represents New Weight Loss Drug Story

Originally posted here:
Weight-Loss Drugs Fuel Rise in US Prescription Spending - Drug Topics

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)	30313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120
Select Your US State	Select Your StateAlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyoming
Program Choice	Select Your ProgramInjectable HGHInjectable TestoteroneInjectable SermorelinInjectable Weight LossInjectable HCG DietInjectable Vitamins
Confirm over 30 years old	Yes
Confirm that you resident in USA	Yes
This is a Serious Inquiry	Yes
Message:

Home » Uncategorized » Weight-Loss Drugs Fuel Rise in US Prescription Spending – Drug Topics